Although smallpox vaccine-associated myopericarditis has been reported, the risk of cardiac ischemic events remains uncertain. We identified personnel receiving the smallpox vaccination and compared them to a historical referent population. The rate of cardiac ischemia diagnoses in the 30 days following smallpox vaccination was 140.1 per 100,000 person-years, compared to 143.5 per 100,000 person-years in referent group (RR 1.0 [95% CI: 0.7-1.4]). The rate of cardiac ischemic events in vaccinees was 121.4 per 100,000 person-years before and 175.7 after adopting pre-vaccination cardiac screening (RR 1.4 [95% CI: 0.8-2.7]). Implementation of pre-vaccination cardiac risk factor screening was not associated with a reduction in cardiac events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2007.09.064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The historical evolution of smallpox treatment in Japan visualised through Japanese artwork and woodblock prints.
J R Coll Physicians Edinb
December 2024
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Art reveals core human emotions during catastrophes like epidemics, allowing people to narrate their coping stories. This review examines smallpox's historical evolution and treatment in Japan, integrating visual art with medical history. It provides chronological insights from smallpox's arrival and traditional remedies to the era of vaccination and public health measures leading to eventual eradication.
View Article and Find Full Text PDFModified Vaccinia Virus Ankara Selectively Targets Human Cancer Cells With Low Expression of the Zinc-Finger Antiviral Protein.
J Med Virol
January 2025
National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Oncolytic viruses are emerging as promising cancer therapeutic agents, with several poxviruses, including vaccinia virus (VACV) and myxoma virus, showing significant potential in preclinical and clinical trials. Modified vaccinia virus Ankara (MVA), a laboratory-derived VACV strain approved by the FDA for mpox and smallpox vaccination, has been shown to be incapable of replicating in human cells unless zinc finger antiviral protein (ZAP) is repressed. Notably, ZAP deficiency is prevalent in various cancer types.
View Article and Find Full Text PDFEvolutionary variation of the monkeypox virus detected for the first time in Nantong, Jiangsu.
Virol J
December 2024
Key Laboratory of Medicine, Nantong Center for Disease Control and Prevention, 189 GongnongnanRoad, Chongchuan District, Nantong, 226007, China.
Monkeypox (MPOX) is a zoonotic disease caused by Orthopoxvirus monkeypox (MPXV), belonging to the Orthopoxvirus genus, and exhibits symptoms similar to smallpox. In 2024, the monkeypox outbreak in the Democratic Republic of the Congo continued to develop, raising widespread global public health concerns. In September 2023, the first local monkeypox outbreak was reported in Nantong, Jiangsu Province, China.
View Article and Find Full Text PDFEffectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
J Med Virol
December 2024
SR Sanjeevani Hospital, Kalyanpur, Siraha, Nepal.
Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.
View Article and Find Full Text PDFMonkeypox (Mpox): Diagnosis and Emerging Challenges.
Yale J Biol Med
December 2024
Multidisciplinary Research Unit, Maulana Azad Medical College and Associated Hospital, New Delhi, India.
Monkeypox (Mpox) has once again been designated a Public Health Emergency of International Concern (PHEIC) as of August, 2024. The severity of the disease is underscored by its significant mortality rate, and unfortunately, there are no targeted therapeutics currently available for this viral infection. Management relies on preventive measures and the use of existing smallpox vaccines due to their genetic similarity to the Mpox virus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!